Notable Labs CEO Thomas Bock resigns
PremiumThe FlyNotable Labs CEO Thomas Bock resigns
3M ago
Notable Labs Advances with Phase 2 Trial for Volasertib
Premium
Company Announcements
Notable Labs Advances with Phase 2 Trial for Volasertib
3M ago
Notable Labs receives FDA clearance to proceed further with volasertib study
Premium
The Fly
Notable Labs receives FDA clearance to proceed further with volasertib study
4M ago
Notable Labs management to meet with Maxim Group
PremiumThe FlyNotable Labs management to meet with Maxim Group
6M ago
Notable Labs management to meet with Maxim Group
Premium
The Fly
Notable Labs management to meet with Maxim Group
6M ago
Notable Labs management to meet with Maxim Group
Premium
The Fly
Notable Labs management to meet with Maxim Group
6M ago
Notable Labs reports 2023 EPS ($3.41) vs. ($21.97) last year
PremiumThe FlyNotable Labs reports 2023 EPS ($3.41) vs. ($21.97) last year
7M ago
Two new option listings and  option delistings on March 25th
Premium
The Fly
Two new option listings and option delistings on March 25th
8M ago
Notable Labs Advances Phase 2 Trial for Volasertib
Premium
Company Announcements
Notable Labs Advances Phase 2 Trial for Volasertib
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100